Squamous Cell Carcinoma of Unknown Primary
Associated Genetic Biomarkers
NCI Definition: A squamous cell carcinoma which has metastasized to another anatomic site and the original site of growth has not been identified. 
Squamous cell carcinoma of unknown primarys most frequently harbor alterations in TP53, CDKN2A, KMT2D, PIK3CA, and NOTCH1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, KMT2D Mutation, and PIK3CA Mutation are the most common alterations in squamous cell carcinoma of unknown primary .
There are 5 clinical trials for squamous cell carcinoma of unknown primary, of which 5 are open and 0 are completed or closed. Of the trials that contain squamous cell carcinoma of unknown primary as an inclusion criterion, 5 are phase 2 (5 open).
CDKN2A and HPV are the most frequent gene inclusion criteria for squamous cell carcinoma of unknown primary clinical trials .
Isa101b, avelumab, and cemiplimab are the most common interventions in squamous cell carcinoma of unknown primary clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.